Table 1:
Demographics for each cohort within the feasibility and applicability groups of this study. Values are reported as percent for discrete variables and medians with the first and third quantiles for continuous variables. P-values are with respect to the corresponding pediatric cohort for the feasibility groups and with respect to the pediatric healthy group for the applicability group. Significant differences are bolded.
| N | % Male | % Healthy | Age | FEV1 % | FVC % | FEV1/FVC% | DLCO % | SpO2 Drop | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Median, N [Q1-Q3] (P-value) | ||||||||||
|
| ||||||||||
| Feasibility Cohorts |
Pediatric | 45 | 55.6 | 15.6 | 10.0 [8.3–13.7] |
86, N=34 [71–101] |
88, N=34 [72–104] |
85, N=34 [78–90] |
77, N=15 [66–101] |
4, N=44 [2–7] |
| Adult | 32 | 40.6 (0.20) |
28.1 (0.18) |
29.7
[22.8–44.4] (<0.01) |
90, N=13 [84–100] (0.17) |
98, N=13 [81–109] (0.15) |
80, N=13 [77–85] (0.06) |
98, N=5 [52–110] (0.48) |
7, N=27
[4–8] (0.02) |
|
|
| ||||||||||
| Pediatric Applicability Cohorts |
Healthy | 5 | 60 | − | 8.8 [7.0–11.1] |
110, N=1 [N/A] |
115, N=1 [N/A] |
86, N=1 [N/A] |
N/A, N=0 | 3, N=5 [2–6] |
| BMT | 12 | 58 (0.45) |
− | 12.6 [8.5–17.4] (0.28) |
83, N=12 [61–100] (0.05) |
82, N=12 [65–96] (0.05) |
89, N=12 [79–93] (0.34) |
77, N=8 [67–84] (N/A) |
9, N=12
[6–16] (0.02) |
|
| BPD | 4 | 50 (0.69) |
− | 7.4 [5.7–9.0] (0.52) |
77, N=2 [65–88] (0.11) |
86, N=2 [74–97] (0.11) |
82, N=2 [81–82] (0.11) |
109, N=2 [92–125] (N/A) |
2, N=4 [2–4] (0.20) |
|
| CF | 8 | 63 (0.56) |
− | 9.9 [9.2–11.6] (0.44) |
91, N=8 [83–107] (0.17) |
102, N=8 [92–106] (0.22) |
79, N=8 [76–86] (0.22) |
125, N=2 [125–125] (N/A) |
6, N=8 [3–6] (0.15) |
|
| chILD | 5 | 40 (0.46) |
− | 13.5 [7.2–16.4] (0.84) |
73, N=5 [59–85] (0.07) |
79, N=5 [63–90] (0.07) |
84, N=5 [78–88] (0.19) |
76, N=3 [57–93] (N/A) |
3, N=5 [0–13] (0.46) |
|